|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Amelioration of atherosclerosis in these diabetic/atherosclerotic animals by soluble RAGE occurred in the absence of changes in plasma lipids or glycemia, emphasizing the contribution of a lipid- and glycemia-independent mechanism(s) to atherogenesis, which we postulate to be interaction of RAGE with its ligands.
|
10082470 |
1999 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
LHGDN |
RAGE axis: Animal models and novel insights into the vascular complications of diabetes.
|
15155381 |
2004 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The receptor for advanced glycation end products (RAGE) is thought to play a critical role in diabetic atherosclerosis.
|
15547674 |
2004 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Studies in rodent models of diabetes suggest that blockade or genetic modification of RAGE suppress diabetes-associated progression of atherosclerosis, exaggerated neointimal expansion consequent to acute arterial injury, and cardiac dysfunction.
|
16305050 |
2004 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
|
17761193 |
2007 |
|
Atherosclerosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In total, nine SNPs of RAGE were analyzed in individuals with and without type 2 diabetes in CODAM: a cohort study of diabetes and atherosclerosis, Maastricht.
|
18079485 |
2008 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
LHGDN |
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice.
|
18079965 |
2008 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The expression of RAGE is up-regulated in atherosclerotic plaques of diabetic animals, and the augmentation of atherosclerosis in diabetic mice is inhibited by the competition of RAGE.
|
18089449 |
2008 |
|
Atherosclerosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The -374T/A polymorphism of the Receptor for Advanced Glycation End products (RAGE) may exert a protective effect toward the development of atherosclerosis.
|
18279705 |
2008 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Strategies to reduce the ligation of AGEs to their receptors such as agents which reduce AGE accumulation, soluble RAGE which acts as a competitive antagonist to the binding of AGEs to RAGE and genetic deletions of RAGE appear to attenuate diabetes associated atherosclerosis.
|
18473849 |
2008 |
|
Atherosclerosis
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.
|
18777492 |
2008 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
RAGE has been extensively implicated in inflammatory states such as atherosclerosis, but the role of S100A12 as its ligand is less clear.
|
19875725 |
2010 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Interestingly, the accelerated atherosclerosis could be prevented by RAS inhibition, or markedly reduced by RAGE blockade, probably through anti-inflammatory and antioxidative effects.
|
19939336 |
2009 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation.
|
20372816 |
2010 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
RGD |
High expression of AGE and RAGE in the livers and arteries of rats with NASH may contribute to the pathogenesis of NASH and early atherosclerosis.
|
20835270 |
2010 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Proinflammatory cell activation via the receptor for advanced glycation end products (RAGE) pathway may play a central pathogenetic role in atherosclerosis.
|
21472666 |
2011 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Receptor for advanced glycation end products (RAGE) and its multiple ligands have been implicated in the pathogenesis of accelerated atherosclerosis; however, little is known about the effects of RAGE activation on vascular calcification.
|
21512281 |
2011 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Soluble receptor for advanced glycation end products RAGE (sRAGE), a secretory form of RAGE, plays an important role in suppressing RAGE signals that induce pro-inflammatory gene activation in a range of inflammatory diseases, such as Alzheimer's disease, complications of diabetes mellitus and atherosclerosis.
|
23708564 |
2013 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore these results suggested that first, RAGE activation may be important in mediating AngII-induced atherogenesis, and second, AngII activation is a major pathway in the development of atherosclerosis.
|
23936343 |
2013 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Receptor for advanced glycation end products (RAGE) is a cell-surface molecule member of the immunoglobulin superfamily and thought to play a critical role in diabetic atherosclerosis.
|
24078092 |
2013 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetics of Plasma Soluble Receptor for Advanced Glycation End-Products and Cardiovascular Outcomes in a Community-based Population: Results from the Atherosclerosis Risk in Communities Study.
|
26083729 |
2015 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Advanced glycosylation end product-specific receptor (AGER) signaling has been implicated in atherosclerosis.
|
26226616 |
2015 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
We also outline novel treatments targeting the AGE-RAGE axis and specific Nox isoforms, which hold great promise in attenuating the development of diabetes-associated atherosclerosis and diabetic nephropathy.
|
26323666 |
2015 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
For example, soluble RAGE reduces murine atherosclerosis and vascular inflammation.
|
26515415 |
2015 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Multiligand receptor for advanced glycation end products (RAGE), osteoprotegerin, and Golgb1 genes may be implicated in atherosclerosis and vascular diseases.
|
26664786 |
2015 |